Cargando…

Investigating the Relationship between of Vascular Endothelial Growth Factor and HER-2neu in IHC Staining with Metastasis and Mortality in Patients with Osteosarcoma

BACKGROUND: The expression of HER-2neu and vascular endothelial growth factor (VEGF) in patients with osteosarcoma may determine the response to treatment. These two factors are likely to be effective in cancer progression. This study aimed at investigating the prevalence of these two factors in the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aznab, Mozaffar, Khajevand Ahmady, Meisam, Jamshidi, Khodamrad, Madani, Seyed Hamid, Khazaei, Sedigheh, Shoushtaryzadeh, Tina, Bagheri, Abolfazl
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	West Asia Organization for Cancer Prevention 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7798143/ https://www.ncbi.nlm.nih.gov/pubmed/33112560 http://dx.doi.org/10.31557/APJCP.2020.21.10.3005

Ejemplares similares

Comparison of Immunohistochemical Methods (IHC) and Fluorescent in Situ Hybridization (FISH) in the Detection of HER 2 /Neu Gene in Kurdish Patients with Breast Cancer in Western Iran
por: Aznab, Mozafar, et al.
Publicado: (2022)

The Role of Human Epidermal Growth Factor Receptor (HER2/neu) in the Prognosis of Patients with Gastric Cancer
por: Aznab, Mozaffar, et al.
Publicado: (2019)

Relationship between the Expression of the Thymidylate Synthase and the Prognosis of Gastric Cancer Patients Treated with Combinational Chemotherapy Regimen Including Fluorouracil, Docetaxel and Cisplatin
por: Aznab, Mozaffar, et al.
Publicado: (2020)

Stevens-Johnson Syndrome Patient Received Combination Chemotherapy Gemcitabine, Cisplatin, and 5-FU for Biliary Tract Cancer
por: Aznab, Mozaffar, et al.
Publicado: (2016)

Evaluation of HER-2/neu status in breast cancer specimens using immunohistochemistry (IHC) & fluorescence in-situ hybridization (FISH) assay
por: Goud, Kalal Iravathy, et al.
Publicado: (2012)

Immunohistochemistry (IHC) staining of in-vitro cancer cell-generated tumoroids
por: Amereh, Meitham, et al.
Publicado: (2023)

Automated sequential chromogenic IHC double staining with two HRP substrates
por: Petersen, Kenneth Heesche, et al.
Publicado: (2018)

Cytoplasmic Her2/neu Immunohistochemical Staining in Breast Cancer; From a Molecular Point of View
por: Safaei, Akbar, et al.
Publicado: (2019)

Predicting IHC staining classes of NF1 using features in the hematoxylin channel
por: Zhang, Wei, et al.
Publicado: (2023)

Evaluation of COVID 19 infection in 279 cancer patients treated during a 90-day period in 2020 pandemic
por: Aznab, Mozaffar
Publicado: (2020)

Breast Cancer and Her-2/Neu
por: Sherwood, Roy
Publicado: (2005)

HER-2/neu and E-cadherin Expression and Microsatellite Instability in Gastric Dysplasia
por: Ahmadi, L, et al.
Publicado: (2011)

The Society for Immunotherapy in Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation
por: Taube, Janis M, et al.
Publicado: (2020)

Predict Ki-67 Positive Cells in H&E-Stained Images Using Deep Learning Independently From IHC-Stained Images
por: Liu, Yiqing, et al.
Publicado: (2020)

HER-2/neu diagnostics in breast cancer
por: Carney, Walter P, et al.
Publicado: (2007)

The Clinical Importance of the Heterogeneity of HER2 neu
por: Davila, Enrique, et al.
Publicado: (2010)

Secondary Myelodysplastic Syndrome May Happen Same as Paraneoplastic Syndrome in a Period of Time and Prior to The Appearance of Malignancy: A case Study of 6 Patients
por: Aznab, Mozaffar, et al.
Publicado: (2013)

Her2/neu Expression in Wilms' Tumor and Correlation With Histopathologic Findings
por: Babashahi, Mashaallah, et al.
Publicado: (2013)

Correction: The Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation
Publicado: (2020)

Allred Scoring of ER-IHC Stained Whole-Slide Images for Hormone Receptor Status in Breast Carcinoma
por: Ahmad Fauzi, Mohammad Faizal, et al.
Publicado: (2022)

Is There any Concordance between of IHC with FISH in HER2-Positive Breast Cancer Patients?
por: Payandeh, Mehrdad, et al.
Publicado: (2017)

Long-term Results of Adjuvant Imatinib Treatment for Localized Gastrointestinal Stromal Tumors after Surgery
por: Aznab, Mozaffar, et al.
Publicado: (2018)

HER2-HER3 dimer quantification by FLIM-FRET predicts breast cancer metastatic relapse independently of HER2 IHC status
por: Weitsman, Gregory, et al.
Publicado: (2016)

Identify AGAP2 as prognostic biomarker in clear cell renal cell carcinoma based on bioinformatics and IHC staining
por: Xu, Zekun, et al.
Publicado: (2023)

HER 2/neu protein expression in colorectal cancer
por: Schuell, B, et al.
Publicado: (2006)

HER-2/neu Testing and Therapy in Gastroesophageal Adenocarcinoma
por: Moelans, Cathy B., et al.
Publicado: (2010)

Anti-HER2/Neu passive-aggressive immunotherapy
por: Mortenson, Eric D, et al.
Publicado: (2014)

HER2/neu testing in primary colorectal carcinoma
por: Ingold Heppner, B, et al.
Publicado: (2014)

Review of the Role of HER2/neu in Colorectal Carcinomas
por: Achalla, Lakshmi Sai Vijay, et al.
Publicado: (2022)

Functional assay for HER-2/neu demonstrates active signalling in a minority of HER-2/neu-overexpressing invasive human breast tumours.
por: DiGiovanna, M. P., et al.
Publicado: (1996)

Adjuvant effect of HER-2/neu-specific adenoviral vector stimulating CD8(+) T and natural killer cell responses on anti-HER-2/neu antibody therapy for well-established breast tumors in HER-2/neu transgenic mice
por: Chen, Y, et al.
Publicado: (2011)

Anti-Her-2/neu antibody induces apoptosis in Her-2/neu overexpressing breast cancer cells independently from p53 status
por: Brodowicz, T, et al.
Publicado: (2001)

Determination of Clinical Process and Response Rate to Treatment in Patients with Gestational Trophoblastic Neoplasia (GTN) with Low and High Risk and Evaluation of Their First Pregnancy Outcome
por: Aznab, Mozaffar, et al.
Publicado: (2018)

Signature maps for automatic identification of prostate cancer from colorimetric analysis of H&E- and IHC-stained histopathological specimens
por: Leng, Ethan, et al.
Publicado: (2019)

Impact of the OncotypeDX score and HER2 RNA PCR levels on HER2-low IHC levels in primary and metastasized tumors
por: Feldman, Didi, et al.
Publicado: (2023)

Comparison of immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) assessment for Her-2 status in breast cancer
por: Sui, Weiguo, et al.
Publicado: (2009)

A comparative study of gastric adenocarcinoma HER2 IHC phenotype and mass spectrometry-based quantification
por: Xu, Bin, et al.
Publicado: (2023)

HER-2/neu oncogene: what does amplification mean?
por: Pavy, J. J., et al.
Publicado: (1993)

Serological Her2/neu-determination in patients receiving Herceptin(®)
por: Thomas, A, et al.
Publicado: (2001)

HER2/neu-directed therapy for biliary tract cancer
por: Javle, Milind, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_9j0o5n6b3oitt75lul7kjao6fv